Insulin Resistance in Women With Prolactinoma

Insulin Resistance and Lipid Profile in Non-Obese Women With Prolactinoma Treated With Dopamine Agonists

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00481299

Enrollment

2004

Registered

2007-06-01

Start date

2004-10-31

Completion date

2006-09-30

Last updated

2007-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia, Insulin Resistance, Prolactinoma

Keywords

Insulin, glucose, lipids, prolactinoma, hyperprolactinemia

Brief summary

Prolactin is suggested to influence insulin resistance, but scarce data is available on the metabolic profile of patients with prolactinoma. The purpose of the protocol was to evaluate cardiovascular disease risk factors in women with prolactinoma treated with dopamine agonists and to study the influence of disease control and anthropometry on their metabolic profile.

Detailed description

A cross-sectional study was performed in non-obese premenopausal women with prolactinoma treated with dopamine agonists evaluated regarding glucose, insulin, Homeostasis Model Assessment (HOMA), lipid profile, C reactive protein (CRP), body mass index (BMI), waist circumference, prolactin, estradiol, testosterone, and sex hormone binding globulin (SHBG). They were compared with control women of similar age and BMI distribution.

Interventions

None listed

Study design

Observational model

DEFINED_POPULATION

Time perspective

OTHER

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 48 Years

Healthy volunteers

Yes

Inclusion criteria

* Prolactinoma * Female gender * Premenopausal

Exclusion criteria

* Obesity (BMI ≥ 30 kg/m²) * Diabetes mellitus * Hypertension * GH deficiency * Hypothyroidism * Primary hypogonadism * Adrenal insufficiency * Pituitary surgery

Countries

Brazil

Outcome results